

Figure 2 shows a coomassie stained SDS-PAGE gel with purified recombinant Bet v 1-monomer and Bet v 1-polymers.

Figures 3(A)-3(C) show the IgE reactivity of birch-pollen allergic patients with nitro-cellulose-blotted purified recombinant Bet v 1-monomer, dimer and trimer.

Figures 4(A)-4(D) show the determination of IgE reactivity of sera from birch pollen allergic patients with Bet v 1-monomer and polymers by ELISA.

Figures 5(A)-5(D) show the inhibition of IgE-binding to recombinant Bet v 1-monomer using Bet 1-polymers.

Figure 6 shows serum IgG<sub>1</sub>-reactivity of Bet v 1-polymer immunized mice with recombinant Bet v 1.

Figure 7 shows the capacity of recombinant Bet v 1-polymers to induce histamine release.

Figures 8(A)-8(B) show binding of monoclonal anti-Bet v 1-antibodies to Bet v 1-derived peptides.

Please replace the paragraph beginning on page 5, line 15, with the following rewritten paragraph:

--The second aspect of the invention is specific hyposensitization therapy. This therapy may be performed as known in the art for

A<sup>2</sup> ut protein allergens and encompasses administering repeatedly to the mammal, typically a human individual, suffering from type I allergy against the protein allergen an immunogen that is capable of raising as IgG immune response against the protein allergen. Administration may be done systemically, for instance by injection, infusion, etc., but also the oral route has been suggested in order to expose the intestinal part of the immune system. The immunogen may be admixed with suitable adjuvants such as aluminium oxide. See further Norman PS, "Current status of immunotherapy for allergies and anaphylactic reactions" Adv. Internal. Medicine 41 (1996) 681-713.

---

Please replace the paragraph beginning on page 10, line 12, with the following rewritten paragraph:

--**Figures 5(A) to 5(D). Inhibition of IgE-binding to recombinant Bet v 1-monomer using Bet v 1-polymers.**

A<sup>3</sup> Sera from 4 birch-pollen allergic patients (A-D) were preincubated with different concentrations (5µg, 500ng, 50ng and 5ng) of purified, recombinant Bet v 1-monomer, Bet v 1-dimer and Bet v 1-trimer. The preincubated sera were then tested for IgE-reactivity to purified, recombinant Bet v 1-monomer by ELISA. The optical densities are displayed on the y-axis.